BILLERICA, Mass. — May 6, 2026 — Leads & Copy — Bruker Corporation (Nasdaq: BRKR) has released its financial results for the three months ending March 31, 2026, showing revenue growth despite headwinds from U.S. academic demand, tariffs, and currency exchange rates.
Bruker’s President and CEO, Frank H. Laukien, noted the company’s first-quarter financial performance exceeded expectations. Bookings for the Bruker Scientific Instruments (BSI) segment grew organically by a high single-digit percentage, with a book-to-bill ratio greater than 1.0x. He cited strong academic orders for post-genomic research solutions from outside the U.S., demand in semiconductor metrology and SciY laboratory software driven by artificial intelligence, and strength in industrial research tools and security detection systems.
Laukien also highlighted the introduction of new products and solutions at scientific and medical conferences, reinforcing Bruker’s position in NMR, spatial biology, and microbiology and molecular diagnostics. The company has reaffirmed its FY26 guidance, anticipating a return to organic revenue growth in the second quarter. Bruker expects to achieve operating margin expansion and double-digit EPS growth in FY2026.
For the first quarter of 2026, Bruker reported revenues of $823.4 million, a 2.7% increase from $801.4 million in the first quarter of 2025. However, revenues decreased organically by 4.4% year-over-year. Growth from acquisitions was 2.6%, and foreign currency translation had a favorable impact of 4.5% year-over-year.
Bruker Scientific Instruments (BSI) revenues were $759.8 million, up 2.1% year-over-year, although organic revenue decreased by 5.0%. Bruker Energy & Supercon Technologies (BEST) revenues totaled $66.9 million, a 12.8% increase year-over-year, with an organic revenue increase of 3.0%, net of intercompany eliminations.
GAAP operating income for the first quarter was $10.2 million, down from $31.8 million in the same period of 2025. Non-GAAP operating income was $84.2 million, compared to $101.7 million in the first quarter of 2025, and the non-GAAP operating margin was 10.2%, compared to 12.7% in the previous year.
GAAP diluted earnings per share was $0.02, compared to $0.11 in the first quarter of 2025. Non-GAAP diluted EPS was $0.31, compared to $0.47 in the same period last year.
Bruker continues to project FY26 revenues between $3.57 and $3.60 billion, compared to $3.44 billion in FY25. This represents a 4% to 5% year-over-year reported revenue growth, including organic revenue growth of 1% to 2%, M&A revenue growth contribution of approximately 1.5%, and a foreign currency translation revenue tailwind of approximately 1.5%.
The company anticipates FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. This includes a currency headwind of approximately $0.15, or 8%, implying constant exchange rate (CER) non-GAAP EPS growth of 23% to 25% year-over-year.
Bruker will host a conference call and webcast on May 6, 2026, at 8:00 am Eastern Daylight Time to discuss these results. A telephone replay will be available through June 6, 2026.
Bruker Corporation enables scientists and engineers to make post-genomic discoveries and develop applications to improve human life. The company’s instruments and solutions enable exploration of life and materials at molecular, cellular, and microscopic levels.
Source: Bruker Corporation
